- Home
- IMCR vs LILAK Comparison
IMCR vs LILAK Comparison
Compare IMCR & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- LILAK
- Stock Information
- Founded
- IMCR 2008
- LILAK 2017
- Country
- IMCR United Kingdom
- LILAK Bermuda
- Employees
- IMCR N/A
- LILAK N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- LILAK Cable & Other Pay Television Services
- Sector
- IMCR Health Care
- LILAK Telecommunications
- Exchange
- IMCR Nasdaq
- LILAK Nasdaq
- Market Cap
- IMCR 1.6B
- LILAK 1.1B
- IPO Year
- IMCR 2021
- LILAK N/A
- Fundamental
- Price
- IMCR $35.00
- LILAK $6.34
- Analyst Decision
- IMCR Buy
- LILAK Buy
- Analyst Count
- IMCR 10
- LILAK 3
- Target Price
- IMCR $58.13
- LILAK $10.27
- AVG Volume (30 Days)
- IMCR 389.0K
- LILAK 1.3M
- Earning Date
- IMCR 08-07-2025
- LILAK 08-05-2025
- Dividend Yield
- IMCR N/A
- LILAK N/A
- EPS Growth
- IMCR N/A
- LILAK N/A
- EPS
- IMCR N/A
- LILAK N/A
- Revenue
- IMCR $333,581,000.00
- LILAK $4,441,000,000.00
- Revenue This Year
- IMCR $26.82
- LILAK $2.45
- Revenue Next Year
- IMCR $8.15
- LILAK $3.11
- P/E Ratio
- IMCR N/A
- LILAK N/A
- Revenue Growth
- IMCR 25.75
- LILAK N/A
- 52 Week Low
- IMCR $23.15
- LILAK $4.23
- 52 Week High
- IMCR $41.54
- LILAK $10.93
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- LILAK 61.36
- Support Level
- IMCR $32.20
- LILAK $5.92
- Resistance Level
- IMCR $35.75
- LILAK $6.65
- Average True Range (ATR)
- IMCR 1.31
- LILAK 0.31
- MACD
- IMCR 0.28
- LILAK 0.01
- Stochastic Oscillator
- IMCR 84.94
- LILAK 68.37
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.